(By Balachander) Mylan Inc. (NASDAQ:MYL), one of the world's largest generic drugmakers, announced the launch of generic version of Roche's osteoporosis treatment Bonviva in the UK and Italy.
The Canonsburg, Pennsylvania-based company said the launch of generic Ibandronic Acid tablets expands its strong portfolio of more than 350 products in the UK and 340 products in Italy.
Osteoporosis is the thinning of bone tissue and loss of bone density over time, common in older women.
Ibandronic Acid Film Coated Tablets POM had sales of about 8.5 million euros ($10.65 million) in the UK and sales of about 27 million euros in Italy for the 12 months ending March 2012, according to IMS Health.
[Related -Mylan, Inc. (MYL) Q3 Earnings Preview: Weak Dollar = Strong Profit?]
On Wednesday, Mylan said its subsidiary launched the generic version of Viramune tablets to treat patients living with HIV/AIDS, after final approval from the U.S. health regulators. This expands further the reach of Mylan's global antiretroviral portfolio.
Last week, the company announced the launch of generic version of Sanofi-Aventis' (NYSE: SNY) Plavix blood thinning tablets indicated for acute coronary syndrome. Mylan's Pharmaceuticals Inc. unit has received final clearance from the U.S. health regulators for its Abbreviated New Drug Application (ANDA) for Clopidogrel Tablets USP, 75 mg and 300 mg.
[Related -Pfizer Inc. (PFE) Q3 Earnings Preview: What To Watch?]
Earlier this month, Mylan announced the launch of the generic version of Pfizer's (NYSE: PFE) Lipitor, the top-selling cholesterol controlling drug, in France, Belgium, the UK, the Netherlands and Ireland.
MYL shares, which have been trading in the 52-week range of $15.49 to $25.00, added 0.67 percent to trade at $21.04 on Thursday.